Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma

View source ↗

Summary

An observational study of Rituximab in combination with CHOP as first-line therapy for diffuse large B-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Rituxan/MabThera (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diffuse Large B-Cell Lymphoma | Status: TERMINATED